• Roche’s satralizumab meets endpoints in inflammatory disorder

    • December 3, 2019
    • Posted By : admin
    • 0 Comment
    •   17 views

    Roche has announced data from its SAkuraSky study, in which the investigational medicine “satralizumab” – formerly SA237 – was evaluated for the treatment of neuromyelitis optica spectrum disorder (NMOSD); an inflammatory disorder of the central nervous system.

    The results of the trial found that only eight of 41 patients (20%) treated with satralizumab in combination with baseline immunosuppressant therapy experienced a protocol-defined relapse (PDR), compared to 18 of 42 patients (43%) treated with placebo.

    Further to these findings, 89%, 78% and 74% of patients on satralizumab in combination with baseline therapy were relapse-free at weeks 48, 96 and 144 compared to 66%, 59% and 49% with placebo in combination with baseline therapy.

    In addition, In the AQP4-IgG seropositive subgroup analysis – a group of patients that experience a more severe disease course – three of 27 patients (11%) treated with satralizumab experienced a PDR compared to 12 of 28 patients (43%) treated with placebo

    Overall, the proportion of patients with serious adverse events was similar between the satralizumab and placebo treatment groups and a lower rate of infections (including serious infections) was observed in patients treated with the drug compared with the placebo group.

  17 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!